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Gliotoxin (GT) is a fungal secondary metabolite that has attracted great interest due to
its high biological activity since it was discovered by the 1930s. An inactive derivative
of this molecule, bis(methylthio)gliotoxin (bmGT), has been proposed as an invasive
aspergillosis (IA) biomarker. Nevertheless, studies regarding bmGT production among
common opportunistic fungi, including the Aspergillus genus, are scarce and sometimes
discordant. As previously reported, bmGT is produced from GT by a methyl-transferase,
named as GtmA, as a negative feedback regulatory system of GT production. In order
to analyze the potential of bmGT detection to enable identification of infections caused
by different members of the Aspergillus genus we have assessed bmGT production
within the genus Aspergillus, including A, fumigatus, A. niger, A. nidulans, and A. flavus,
and its correlation with gtmA presence. In order to validate the relevance of our in vitro
findings, we compared bmGT during in vitro culture with the presence of bmGT in sera
of patients from whom the Aspergillus spp. were isolated. Our results indicate that most
A. fumigatus isolates produce GT and bmGT both in vitro and in vivo. In contrast, A. niger
and A. nidulans were not able to produce GT or bmGT, although A. niger produced
bmGT from a exogenous GT source. The frequency and amount of bmGT production
in A. terreus and A. flavus isolates in vitro was lower than in A. fumigatus. Our results
suggest that this defect could be related to the in vitro culture conditions, since isolates
that did not produce bmGT in vitro were able to synthetize it in vivo. In summary, our
study indicates that bmGT could be very useful to specifically detect the presence of
A. fumigatus, the most prevalent agent causing IA. Concerning A. terreus and A. flavus
a higher number of analyses from sera from infected patients will be required to reach a
useful conclusion.
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INTRODUCTION
More than 20 years ago the first invasive aspergillosis (IA)
biomarker, galactomannan (GM), was developed based on an
enzyme linked immunosorbent assay (Stynen et al., 1995). It
stirred up the diagnosis of this lethal infectious disease, as it
allowed to detect the infection when combined with clinical
signs and symptoms (Maertens et al., 1999, 2002). During the
last few years, the biomarker weaponry has arisen with the
development of a system to detect β-D-glucan, Aspergillus PCR
and lateral flow device to detect an Aspergillus-derived protein
among others (Odabasi et al., 2004; Thornton, 2008; White
et al., 2015). New diagnostic approaches were developed based
on the increased accuracy of these tests, such as pre-emptive
therapy (Wingard, 2007; Riwes and Wingard, 2012). Despite
of these advances, IA management continues to be challenging
due to the heterogeneous population at risk, the diversity of
clinical and radiological presentations and the lack of a gold
standard (Lamoth and Calandra, 2017). Thus, at present, it is
required to understand the limitations of each biomarker and
the corresponding diagnosis test in order to accurately diagnose
these challenging infections (Maertens et al., 2016). In this line,
the future directions in IA diagnosis research need to focus on the
development of new biomarkers, including a clear understanding
of their strengths and limitations, along with the assessment
of their utility in well-designed clinical trials (Arvanitis and
Mylonakis, 2015; Mercier and Maertens, 2017).
In recent years, bis(methylthio)gliotoxin (bmGT) has
generated great interest as an IA biomarker (Maertens et al.,
2016; Mercier and Maertens, 2017). Its detection in serum
by High Performance Thin Layer Chromatography (HPTLC)
was shown to be reliable (Domingo et al., 2012). Moreover,
it has been clinically validated in a small prospective study
in comparison with GM quantification (Vidal-García et al.,
2016). Data suggest a good diagnostic performance (61.5%
sensitivity and 93% specificity) and importantly, high positive
and negative predictive values when used in combination with
GM detection (100% and 97.5%, respectively), which suggest
a potential utility in pre-emptive approaches. Pending further
validation, unlike GM, bmGT detection could be useful in
non-immunocompromised populations as it was previously
found to be positive in a non-compromised patient suffering
from IA that presented negative GM values (Vidal-García
et al., 2017). Nevertheless, data regarding the frequency and
distribution of bmGT production by different opportunistic
molds are scarce and in most cases based on bioinformatics
analysis (Bergmann et al., 2007; Andersen et al., 2013;
Dolan et al., 2014). These data would be very important
for understanding the specificity and the clinical sensitivity
of this biomarker to differentiate between species within
the Aspergillus genus and, thus, treat this infection more
effectively.
Bis(methylthio)gliotoxin is an inactive derivative of gliotoxin
(GT). A. fumigatus is, to date, the most important opportunistic
fungi producing bmGT (Li et al., 2006; Guimarães et al., 2010;
Domingo et al., 2012; Sun et al., 2012; Liang et al., 2014). BmGT
serves as a negative regulator of the GT biosynthesis, and it is
produced by methylation of GT by an S-adenosylmethionine-
dependent bis-thiomethyltransferase (Dolan et al., 2014, 2015,
2017), eliminating the ability of GT to produce toxic reactive
oxygen species (ROS) (Dolan et al., 2015). BmGT formation
from an exogenous source of GT has been described in A. niger
and A. nidulans (Scharf et al., 2014; Manzanares-Miralles et al.,
2016). The enzyme responsible for bmGT biosynthesis, which
is an S-adenosylmethionine (SAM)-dependent methyltransferase
called GtmA, has been characterized in A. fumigatus; and other
orthologs have been found on species like A. niger or A. terreus
(Dolan et al., 2014; Scharf et al., 2014; Manzanares-Miralles et al.,
2016). The best characterized enzyme is GtmA, which is known
to be encoded by the gtmA gene, located in the chromosome 2
(Dolan et al., 2014). Bioinformatics analysis of the Ascomycota
phylum showed 124 orthologs of GtmA. However, it is known
that toxin production is discontinuous among different species
and it is not clear which species within Aspergillus genus are able
to produce GT and, subsequently, the inactive derivative bmGT
(Gardiner and Howlett, 2005; Patron et al., 2007). The aim of the
present study was to assess the frequency and species distribution
of bmGT within the Aspergillus genus in cultures in vitro as well
as in vivo in sera of patients from whom fungi were isolated.
We also characterized the ability of different clinical isolates
from Aspergillus genus to methylate GT in cultures in vitro,
to confirm the presence and activity of methyltransferases in
Aspergillus species isolated from probable and proven cases of
IA. Our findings indicate that bmGT could be considered as an
specific biomarker to detect infections by A. fumigatus, the most
common agent causing IA, excluding the presence of A. nidulans
and A. niger.
MATERIALS AND METHODS
Gliotoxin and Bis(methylthio)gliotoxin
Production
We analyzed GT and bmGT production within 252 Aspergillus
spp. isolates. Most A. fumigatus complex (n = 119) were
clinical isolates from Canisius-Wilhelmina Hospital, Nijmegen
(Netherlands). Eighteen of those isolates were cryptic species
from Section Fumigati from Gregorio Marañón University
Hospital, Madrid (Spain). Other Aspergillus species were clinical
isolates from Miguel Servet University Hospital, Zaragoza
(Spain) and corresponded to 36 A. flavus complex, 35 A. terreus
complex, 40 A. niger complex, and 22 A. nidulans complex. One
milliliter of 12 McFarland conidial suspension (approximately
3–5 × 107 conidia/mL) was added to 9 mL of liquid medium
(Roswell Park Memorial Institute [RPMI] 1640 + glucose
20 g/L + glutamine 2 mM + HEPES 25 mM) in 50 mL culture
flasks and incubated at 37◦C for 96 h. A 2 mL sample of
supernatant was obtained and frozen at−20◦C and subsequently
used for GT and bmGT detection and quantification by HPTLC
as described below. In those cases where GT and/or bmGT was
not detected, fungal isolates were cultured employing Czapek
Dox Broth (+ glutamine + HEPES) to confirm that this defect
was not specific for RPMI medium. Czapek Dox Broth is a
medium of a different composition to RPMI1640, and similarly to
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the last one, it is commonly used in Aspergillus cultures in vitro.
Thus, we decided to compare both in order to discard effects
relative to specific culture media conditions in vitro.
Bis(methylthio)gliotoxin Production From
Exogenous Gliotoxin
Bis(methylthio)gliotoxin production from an exogenous source
of GT was assessed in a total of 35 isolates of the species
complexes A. flavus (n = 12), A. terreus (n = 9), A. niger
(n = 8), and A. nidulans (n = 6). Conidial inoculum was prepared
as described above and added to 50 mL culture flasks with
Czapek Dox Broth (+ glutamine+HEPES). These cultures were
incubated at 37◦C for 45 h. At 45 h, GT was added to a final
concentration of 2.5 mg/L and methanol was added as solvent
control. At 0, 3, and 6 h, 2 mL aliquots of supernatant were taken
and frozen until GT and bmGT analysis.
Detection of Bis(methylthio)gliotoxin in
Sera From IA Patients
We assessed sera from patients hospitalized in the Miguel Servet
University Hospital with probable/proven IA according to the
EORTC/MSG definitions (De Pauw et al., 2008). We included
in the study those cases with Aspergillus spp. growth in clinical
samples. Serum were prospectively collected and frozen at−20◦C
until GT and bmGT detection. All protocols were supervised
and approved by the Ethics Committee of Clinical Research from
Aragón (CEICA), number PI15/0203.
Metabolite Identification and
Quantification by High Performance Thin
Layer Chromatography (HPTLC)
Gliotoxin and bis(methylthio)gliotoxin detection and
quantification were performed both in serum and supernatant
samples by HPTLC as described by Domingo et al. (2012). Briefly,
GT and bmGT were extracted together using dichloromethane.
After agitation and two phase’s separation, non-aqueous phase
was added onto silica gel plates. Then, they were developed
using a horizontal development chamber (Camag). The mobile
phase was a mixture of tetrahydrofuran/n-heptane/acetonitrile
(40:58:2 [v/v/v]). After 25 min development, plates were scanned
with an ultraviolet scanning densitometry (TLC Scanner 3,
Camag; λ = 280 and 367 nm; linear scanning). GT and bmGT
identification was performed by retention time and spectral
analysis and quantification was performed by peak area under
curve analysis using Camag’s personal computer software.
Genetic Detection of gtmA Gene
Chromosomal DNA of Aspergillus spp. isolates was extracted
using cetyltrimethylammonium bromide (Sigma-Aldrich, St.
Louis, MO, United States). The specie-specific primers used for
gtmA detection are summarized in Table 1, along with expected
amplicon length. PCR was performed using HotTaq Master
Mix, (IBIAN Technologies, Zaragoza, Aragón, Spain). An initial
denaturation of 2 min at 94◦C was followed by 35 cycles at 94◦C
for 30 s, 56◦C for 15 s, and 72◦C for 1 min. DNA amplification
products were visualized after electrophoresis on 2% agarose gels.
TABLE 1 | Primers.
Name Sequence (5′–3′) Amplification
length (bp)
A. terreus Fw TCG GAG GCC CTA AAC CG 291
A. terreus Rv GGA TTC GGA AGT CCA ACA AGG
A. flavus Fw TCA AGC GTC CTT CAT CAT AC 289
A. flavus Rv TCG TCA GGG AAG AGA TTA AAA GC
A. niger Fw TCT AGT GCC CTT CAT CGT GC 223
A. niger Rv TCG TCA GGG AAG AGG TTG AAC
A. fumigatus Fw TCC AGC GTA CTC AAC CAC AC 293
A. fumigatus Rv CGT CTG GAA AGA TCT GGA AG
ITS 1 Fw TCC GTA GGT GAA CCT GCG G 565 to 613
ITS 4 Rv TCC TCC GCT TAT TGA TAT G
UView 6x loading dye (Bio-Rad, Hercules, CA, United States) was
used for nucleic acid staining. As a length standard 0.1–1 kbp
molecular mass marker was used.
Statistical Analysis
Statistical analyses were performed using Prism 6, Graphpad
(San Diego, CA, United States). GT and bmGT concentration
in culture filtrates are given as mean ± standard error of mean
(SEM). A significance level of 0.05 was considered statistically
relevant for multiple comparison test and chi-square test, as
appropriate.
RESULTS
Gliotoxin and Bis(methylthio)gliotoxin
Production by Aspergillus spp. Isolates
The production of GT and bmGT was tested in culture
supernatants of 252 Aspergillus isolates from the species
complexes A. fumigatus, A. flavus, A. terreus, A. niger, and
A. nidulans after 4 days of incubation. Non-cryptic A. fumigatus
isolates (n = 101) produced GT and bmGT at highest frequencies,
77.23% and 84.16%, respectively. Among the five cryptic
species analyzed: A. calidoustus (n = 1), A. fumigatiaffinis
(n = 3), A. lentulus (n = 11), N. udagawae (n = 2), and
A. novofumigatus (n = 1), all but the last produced GT and/or
bmGT. A. fumigatiaffinis seemed to be the most frequent GT
and bmGT producing species, as the three tested isolates (100%)
produced bmGT. In contrast, just two of the eleven isolates
(18%) of A. lentulus produced bmGT. BmGT was also more
frequently detectable than GT in culture supernatants of A. flavus,
11.11% vs. 8.33%, respectively. In contrast, A. terreus produced
GT more frequently than bmGT (22.86% vs. 2.86% respectively)
(Figure 1). Notably, none of the A. niger and A. nidulans isolates
tested produced GT and/or bmGT. All cultures were analyzed by
HPTLC, a method to detect GT and bmGT previously optimized
and validated versus LC-MS (Domingo et al., 2012), and some
of the results in selected culture isolates of A. fumigatus, A.
niger, A. nidulans, and A. flavus, were confirmed by LC-MS
(data not shown). The absence of GT and/or bmGT production
was not specific for the culture conditions in vitro since culture
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FIGURE 1 | Percentage of gliotoxin and bis(methylthio)gliotoxin producing isolates among different Aspergillus species.
FIGURE 2 | Mean concentrations of gliotoxin and bis(methylthio)gliotoxin
detected in culture supernatans of different Aspergillus species. ∗∗∗Statistically
significant differences (p < 0.001).
of GT/bmGT negative fungal isolates employing Czapek Dox
Broth yielded similar results (data not shown). In addition, the
differences were not due to different fungal growth since cell
cultures showed a similar behavior and growth as analyzed by
XTT reduction assay. Optimal culture conditions, as well as
analytical specificity of the method, were confirmed by employing
cell cultures from an A. fumigatus gliP deletion mutant, which is
unable to produce GT and bmGT (Sugui et al., 2007).
A. fumigatus isolates also produced GT and bmGT in higher
concentration than other Aspergillus spp. did. These differences
were statistically significant (p < 0.05) (Figure 2). The mean
concentration of GT was 2.26 ± 0.40 mg/L and of bmGT
was 3.45 ± 0.44 mg/L for A. fumigatus. A. flavus isolates
yielded a mean concentration of 0.14 ± 0.13 mg/L of GT and
0.39 ± 0.31 mg/L of bmGT. The mean concentration of GT and
bmGT were 0.79± 0.34 mg/L and 0.07± 0.07 for A. terreus.
Bis(methylthio)gliotoxin Production From
Exogenous Gliotoxin
In order to confirm the results obtained in cell cultures
concerning bmGT production, we analyzed the ability of some
fungal isolates to generate bmGT from an external GT source
as well as the presence of methyltransferase genes. This is of
special utility to find out whether the Aspergillus spp. that did
not produce GT and bmGT (A. niger and A. nidulans) are also
unable to methylate exogenous GT. This finding would mean that
these isolates do not express methyl-transferase activity and, thus,
confirm that they are unable to generate bmGT. Moreover, this
would indirectly suggest that they are also unable to generate GT,
since GT methylation has been proposed as a negative feedback
regulatory system, inherent to all GT-producing species.
First, we analyzed if fungal isolates presented GT methyl-
transferase activity by adding pure GT and monitoring the
generation of bmGT. The ability to produce bmGT from an
exogenous source of GT was assessed in the isolates of A. flavus,
A. terreus, A. niger, and A. nidulans that did not produce GT
or bmGT in the previous experiment. All isolates from the
A. flavus (n = 12) and A. terreus species (n = 9) were able to
methylate exogenous GT in order to produce bmGT. Among
A. niger isolates, this ability was less consistent, nevertheless,
5/8 isolates (62.5%) showed such ability. Finally, none of the
A. nidulans isolates (n = 6) methylated GT to generate bmGT
(Figure 3). This result confirms that A. nidulans does not
express methyl-transferase activity and, thus, it is unable to
generate endogenously bmGT, and, likely, GT, in line with
the results of Figure 1. Concerning A. niger, some isolates
seem to express methyl-transferase activity against exogenous
GT. Indeed, it has been previously shown that the methyl-
transferase MT-ii is expressed in A. niger and methylates
exogenous GT (Dolan et al., 2017). However, since they do not
produce GT (Figure 1 and Manzanares-Miralles et al., 2016),
this would explain that they are unable to endogenously produce
bmGT.
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FIGURE 3 | Percentage of GT-methylating isolates of Aspergillus species.
Among bmGT producing isolates, immediately after GT
addition (t = 0 h), this was recovered in a mean concentration
of 0.86 ± 0.04 mg/L. None of the isolates produced bmGT at
this time (Figure 4). At 3 h after GT addition, GT concentration
decreased and bmGT concentration increased. This observation
continued at 6 h, when the maximum bmGT and the minimum
GT concentrations were detected. There were no differences
between mean concentration of GT and bmGT among species
(p > 0.05) indicating a similar methylating activity.
Comparison of Serum bmGT Detection
in Vivo With bmGT Production in in Vitro
Cultures
Our results confirm that most A. fumigatus isolates and some
A. terreus and A. flavus isolates were able to endogenously and
exogenously produce bmGT. However, the frequency of bmGT
production within A. terreus and A. flavus isolates was much
less than in A. fumigatus isolates. Since the analyses of the genes
involved in GT synthesis is difficult due to the complexity of
the pathways involved, we decided to analyze if the isolates
that did not produce endogenously GT and bmGT in vitro,
were able to synthesis bmGT in humans in vivo. To this aim,
we included six cases of probable/proven IA with mycological
growth from whom in vitro cultures had been established and
analyzed. Serum bmGT concentration for these patients, fungal
isolation, sample type and fungal ability to produce bmGT
in vitro (de novo and from exogenous GT) as well as detection
of gtmA gene and the MT-ii homolog are summarized in
Table 2.
All, but one serum, were positive for bmGT. This serum
belonged to a patient with probable IA diagnosed by A. fumigatus
growth in bronchial aspirate. The other three patients with
A. fumigatus isolation had positive bmGT (range 0.19–
13.68 mg/L). There was a case of IA by A. flavus and a case of
IA by A. terreus. Both had detectable bmGT in serum. Notably,
these isolates corresponded to those ones in which we were not
able to detect either endogenous GT or bmGT during in vitro
FIGURE 4 | Bis(methylthio)gliotoxin production from exogenous gliotoxin among different Aspergillus species. The bars represent mean concentrations with
standard error of means.
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TABLE 2 | bmGT production, methylation of exogenous GT and carriage of gtmA or MT-ii genes for Aspergillus spp. isolates from probable and proven invasive
aspergillosis cases.
Case IA type Culture (sample) Serum bmGT
(mg/L)
Specie Supernatant
bmGT (mg/L)
GT methylation
([bmGT]t = 6)
gtmA gene
1 Proven Sinus biopsy 1,66 A. flavus Not detected 0.93 + (mt-ii)
2 Proven Vitreous, thrombus 0,19 A. fumigatus 0.26 ± 0.05 0.90 +
3 Probable (proven IFI) Bronchial aspirate 6,84 A. fumigatus 0.52 ± 0.05 0.55 +
4 Probable Sputum 13,68 A. terreus Not detected 0.16 + (mt-ii)
5 Probable Bronchial aspirate – A. fumigatus 0.48 ± 0.14 0.98 +
6 Probable Sputum 2,6 A. fumigatus 0.18 ± 0.02 0.48 +
FIGURE 5 | Detection of gtmA and mt-ii genes in clinical isolates from probable/proven invasive aspergillosis cases.
culture. Nevertheless, all of them methylated the exogenous
GT and carried the mt-ii methyl-transferase gene, as seen in
Figure 5. Of note, those isolates which produced bmGT in
higher amounts in vitro, did not correlate with the highest bmGT
production in vivo. All the clinical isolates from A. fumigatus
showed the ability to methylate exogenous GT and carry the gtmA
gene.
Finally, in order to confirm that A. nidulans and A. niger did
not produce GT and, thus, are unable to endogenously synthesize
bmGT, we analyze the presence of gliP gene (a critical gene
within the gli cluster responsible for GT synthesis) by PCR.
None of the isolates from A. niger and A. nidulans carry the
gliP gene (data not shown) confirming that they are unable to
produce GT and bmGT, as found in the cell culture analysis
(Figure 1). Moreover, a bioinformatic analyses searching for
the presence of gli cluster homology sequences in the genome
of sequenced A. niger and A. nidulans strains, yielded negative
results, confirming our experimental data and in line with
previous findings (De Pauw et al., 2008; Manzanares-Miralles
et al., 2016). In contrast, sequences with some homology to gli
cluster were found in both A. terreus and A. flavus genomes (data
not shown) as previously indicated (Patron et al., 2007).
DISCUSSION
Despite recent advances, the lack of a single gold standard
technique and the limitations of the available ones, make
diagnosis of IA still challenging (Maertens et al., 2016; Mercier
and Maertens, 2017). In recent years, new metabolite based
diagnostic tools have been under research, such as GT or volatile
organic compounds (Lewis et al., 2005a; Chambers et al., 2009).
Regarding GT, its high biological reactivity and its potential
ability to interact with cells and tissues (Domingo et al., 2012)
make it hard to detect in body fluids (Scharf et al., 2012). This
limitation is overcame by bmGT, which is more stable and
reliably detected in serum (Domingo et al., 2012). It is known
that A. fumigatus produces GT in the highest concentrations
and more frequently than other Aspergillus species (Lewis et al.,
2005b; Kupfahl et al., 2008). This conclusion has been supported
by our results, in which 77% of the A. fumigatus isolates
were GT-producers in significantly higher concentrations and
frequencies than those obtained for A. flavus and A. terreus
species complexes, the other Aspergillus-producing GT species.
With reference to bmGT, A. fumigatus was also the most
common bmGT producing complex. Notably, and in line with
previous findings (De Pauw et al., 2008; Manzanares-Miralles
et al., 2016), neither A. niger or A. nidulans strains were able
to endogenously produce GT and/or bmGT, although methyl-
transferase activity was found in A. niger isolates when using
exogenous GT. These results are supported by both PCR analyses
and bioinformatic studies confirming the absence of the gli
cluster in these species. These findings contrast to previous
studies in which a high proportion of A. niger isolates were shown
to produce GT (Kupfahl et al., 2008). We have no explanation for
these contradictory findings although, in line with our findings,
Kupfahl et al. (2008) did not detect gliP gene in A. niger, which has
been shown to be critical for GT synthesis, at least in A. fumigatus
isolates (Sugui et al., 2007).
Some authors have been interested in the secondary
metabolite profiles of cryptic species of the Fumigati section.
Unlike other authors, we found out that A. lentulus and
A. fumigatiaffinis were able to produce GT and bmGT (Larsen
et al., 2007; Sugui et al., 2010; Tamiya et al., 2015). Regrettably, we
Frontiers in Microbiology | www.frontiersin.org 6 June 2018 | Volume 9 | Article 1246
fmicb-09-01246 June 12, 2018 Time: 13:32 # 7
Vidal-García et al. Bis(methylthio)gliotoxin Production in Aspergillus Genus
just analyzed one isolate of A. calidoustus and A. novofumigatus.
The A. calidoustus isolate was GT and bmGT producer, but
A. novofumigatus was not. This result does not rule out the ability
to produce GT and bmGT by A. novofumigatus since culture
conditions (medium, aeration, temperature, sampling time. . .)
affect to secondary metabolite synthesis (Belkacemi et al., 1999;
Watanabe et al., 2004). This could explain the low GT and bmGT
detection among non-A. fumigatus species since all experiments
were performed in the same conditions and confirmed employing
other culture protocols.
Aiming to avoid such a limitation, we analyzed the ability
to produce bmGT from an exogenous source of GT among
non-toxigenic isolates. We detected bmGT in culture filtrates
of all the A. flavus and A. terreus analyzed, thus suggesting
a consistent ability to produce bmGT. To our knowledge
no specific methyltransferases had been described to date for
these species. Nevertheless, it has been described an ortholog
and a homolog of GtmA for A. terreus and A. flavus by
bioinformatics analysis but it is the first time in which its
expression has been described. In our study, A. niger also
showed the ability to methylate GT, but less frequently.
Curiously, none of the A. nidulans isolates analyzed produced
bmGT even when it has been described that a specific
methyltransferase (and the encoding gene) able to produce
bmGT from GT for this species (Manzanares-Miralles et al.,
2016). This discrepancy could be due to the known fact that
culture conditions do not reflect the genetic potential and
that not all the strains of the same species have the same
metabolic profile (Bergmann et al., 2007). Indeed, secondary
metabolism confers a survival benefit to the producing isolate
and the in vitro culture conditions are not optimal to activate
this survival pathway, depending on the Aspergillus spp. and/or
isolate.
In order to overcome the limitations of the in vitro culture to
analyze secondary metabolism, we have employed some clinical
isolates from patients with probable/proven IA and compared
bmGT production in in vitro culture with bmGT in serum from
those patients. In this scenario, where fungi has to colonize
the host and adapt itself to the new environmental conditions,
the fungi would activate secondary metabolism and display all
potential virulence factors such a GT (Cramer et al., 2006;
Sugui et al., 2007) In these conditions, all but one of the seven
probable/proven patients had bmGT detectable in serum, even
those that did not produce GT and bmGT in vitro. Importantly,
all of them were able to produce bmGT from exogenous GT and
carried an ortholog of GtmA, MT-ii.
In summary, our findings indicate that bmGT production is
useful to diagnose IA caused by A. fumigatus and, at some extent,
by A. terreus and A. flavus, although at a much lower frequency,
since they present the ability to methylate GT and endogenously
produce bmGT in vitro and in vivo. Moreover, and pending of
validation with a higher number of samples, our novel findings
indicate that conclusions about the expression of molecules that
could be used as potential diagnostic biomarkers based on in vitro
fungal cultures cannot be reached unless they are confirmed
in proper in vivo studies employing animal models or patients
suffering from IA.
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